The University of Southampton
University of Southampton Institutional Repository

Management of advanced colorectal cancer: state of the art

Management of advanced colorectal cancer: state of the art
Management of advanced colorectal cancer: state of the art
Colorectal cancer ( CRC) caused over 500 000 deaths worldwide in 2002. Recent advances in the treatment of advanced disease include the incorporation of two new cytotoxic agents, irinotecan and oxaliplatin, into first- line regimens. The concept of planned sequential therapy involving three active agents during the course of a patient's treatment is evolving. Coupled with the integrated use of targeted monoclonal antibodies, we can now expect overall survival rates for advanced disease to exceed 20 months. This review considers current treatments and suggests where future progress may occur
colorectal cancer, first-line, 5-fluorouracil, irinotecan, oxaliplatin, targeted agents
0007-0920
131-138
Saunders, M.
cd8bb634-404f-4a0c-b7e0-dfe855bb3312
Iveson, T.
867cb6c5-ea9a-4521-a4cc-4cd4d2503b3a
Saunders, M.
cd8bb634-404f-4a0c-b7e0-dfe855bb3312
Iveson, T.
867cb6c5-ea9a-4521-a4cc-4cd4d2503b3a

Saunders, M. and Iveson, T. (2006) Management of advanced colorectal cancer: state of the art. British Journal of Cancer, 95 (2), 131-138. (doi:10.1038/sj.bjc.6603233).

Record type: Article

Abstract

Colorectal cancer ( CRC) caused over 500 000 deaths worldwide in 2002. Recent advances in the treatment of advanced disease include the incorporation of two new cytotoxic agents, irinotecan and oxaliplatin, into first- line regimens. The concept of planned sequential therapy involving three active agents during the course of a patient's treatment is evolving. Coupled with the integrated use of targeted monoclonal antibodies, we can now expect overall survival rates for advanced disease to exceed 20 months. This review considers current treatments and suggests where future progress may occur

Full text not available from this repository.

More information

Published date: 2006
Keywords: colorectal cancer, first-line, 5-fluorouracil, irinotecan, oxaliplatin, targeted agents

Identifiers

Local EPrints ID: 62916
URI: http://eprints.soton.ac.uk/id/eprint/62916
ISSN: 0007-0920
PURE UUID: abe5b6d3-1e9d-424d-b4a1-c2284e3bd00f

Catalogue record

Date deposited: 04 Sep 2008
Last modified: 13 Mar 2019 20:26

Export record

Altmetrics

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×